The National Institutes of Health (NIH) has awarded Winston Pharmaceuticals a $375,000 Small Business Innovation Research (SBIR) grant to support Phase 1 development of its civamide nasal spray for the treatment of postherpetic neuralgia (PHN) of the trigeminal nerve (TN). Civamide is a proprietary TRPV-1 receptor modulator that previously received orphan drug designation in the US for the treatment of PHN of the TN. Winston is also developing intranasal civamide for the treatment of cluster headaches.
Winston President and CEO Joel E. Bernstein commented, “We are extremely pleased by the award of this SBIR grant. The development of civamide nasal solution for treatment of PHN of the trigeminal nerve could bring relief to many patients suffering with this severe chronic pain. The use of TRPV-1 modulators in treating neuropathic disease is a unique approach in this area, and this SBIR grant gives us an opportunity to further investigate the use of this class of medications. The availability of an effective and safe treatment, i.e., without systemic effects or drug interactions, would fill an important unmet medical need in the treatment of PHN of the TN.”
Read the Winston press release.
